{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:40:07Z","timestamp":1750005607781,"version":"3.41.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Long-term hepatitis B immunity has been demonstrated following the completion of the primary vaccination series in childhood. Some guidelines recommend a hepatitis B surface antibody (anti-HBs) directed approach following community-acquired needle-stick injury (CANSI) to inform hepatitis B postexposure prophylaxis (PEP) management. We assessed the utility of anti-HBs testing post-CANSI, as well as the costing of, and adherence to PEP at a pediatric hospital.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Children presenting to an Australian tertiary pediatric hospital post-CANSI (2014\u20132019) were identified retrospectively using medical and laboratory records. Immunization status was obtained from the Australian Immunisation Registry.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Fifty-six children with CANSI were identified. Of those with immunization records, all had completed hepatitis B vaccinations (n = 52). At presentation, 44% (n = 23) had anti-HBs &lt;10 IU\/L, which was more likely in older (\u22656 years, 68%) versus younger children (OR 4.59, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.02). HBIG and hepatitis B vaccine adherence was 65% (15\/23) and 78% (18\/23), respectively. All children (n = 14) with anti-HBs \u22654 weeks postvaccination \u00b1HBIG, demonstrated an anamnestic response. No hepatitis B infections were detected. Using completed immunizations versus anti-HBs levels as a marker of immunity to direct PEP resulted in a projected cost savings of AUD$ 4234.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Anti-HBs levels &lt;10 IU\/L, despite previous vaccinations, were frequent in children post-CANSI, with many demonstrating an anamnestic response. Adherence to postexposure HBIG and hepatitis B vaccine was suboptimal using an anti-HBs directed approach. These data support re-evaluating PEP in an era of the national immunization registry; completion of hepatitis B vaccinations as a marker of immunity provides a practical approach, ensuring optimized care for pediatric CANSI.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000003350","type":"journal-article","created":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T03:00:21Z","timestamp":1638586821000},"page":"80-84","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Re-examining Hepatitis B Postexposure Prophylaxis Following Pediatric Community-acquired Needle-stick Injury in an Era of a National Immunization Registry"],"prefix":"10.1097","volume":"41","author":[{"given":"Krist Y.H.","family":"Ewe","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Perth Children\u2019s Hospital, Nedlands, Australia"},{"name":"Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher C.","family":"Blyth","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Perth Children\u2019s Hospital, Nedlands, Australia"},{"name":"Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Australia"},{"name":"School of Medicine, University of Western Australia, Perth, Western Australia"},{"name":"PathWest Laboratory Medicine, Queen Elizabeth II Medical Centre, Nedlands, Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlie","family":"McLeod","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Perth Children\u2019s Hospital, Nedlands, Australia"},{"name":"Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Australia"},{"name":"School of Medicine, University of Western Australia, Perth, Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith L.","family":"Borland","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Western Australia, Perth, Western Australia"},{"name":"Department of Emergency Medicine, Perth Children\u2019s Hospital, Nedlands, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asha C.","family":"Bowen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Perth Children\u2019s Hospital, Nedlands, Australia"},{"name":"Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Australia"},{"name":"School of Medicine, University of Western Australia, Perth, Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel K.","family":"Yeoh","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Perth Children\u2019s Hospital, Nedlands, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita J.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Perth Children\u2019s Hospital, Nedlands, Australia"},{"name":"Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Australia"},{"name":"School of Medicine, University of Western Australia, Perth, Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,12,8]]},"reference":[{"key":"R1-20250615","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jinf.2011.04.002","article-title":"Acute hepatitis B infection following a community-acquired needlestick injury.","volume":"62","author":"Res","year":"2011","journal-title":"J Infect"},{"key":"R2-20250615","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/00006454-199711000-00027","article-title":"Hepatitis B virus infection from a needle stick.","volume":"16","author":"Garc\u00eda-Algar","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"R8-20250615","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0140-6736(83)90624-4","article-title":"Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine.","volume":"2","author":"Beasley","year":"1983","journal-title":"Lancet"},{"key":"R9-20250615","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00006454-199104000-00007","article-title":"The protective efficacy of recombinant hepatitis B vaccine in newborn infants of hepatitis B e antigen-positive-hepatitis B surface antigen carrier mothers.","volume":"10","author":"Lee","year":"1991","journal-title":"Pediatr Infect Dis J"},{"key":"R10-20250615","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00004836-199201000-00007","article-title":"Impaired response to recombinant hepatitis B vaccine in HIV-infected persons.","volume":"14","author":"Bruguera","year":"1992","journal-title":"J Clin Gastroenterol"},{"key":"R13-20250615","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.vaccine.2012.11.037","article-title":"Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine.","volume":"31","author":"Gilca","year":"2013","journal-title":"Vaccine"},{"key":"R14-20250615","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.4161\/hv.34393","article-title":"The persistence of anti-HBs antibody and anamnestic response 20 years after primary vaccination with recombinant hepatitis B vaccine at infancy.","volume":"10","author":"Bagheri-Jamebozorgi","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"R15-20250615","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/01.inf.0000154329.00361.39","article-title":"Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country.","volume":"24","author":"Duval","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"R16-20250615","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.vaccine.2009.10.074","article-title":"Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand.","volume":"28","author":"Poovorawan","year":"2010","journal-title":"Vaccine"},{"key":"R17-20250615","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/j.vaccine.2011.01.025","article-title":"Antibody levels and immune memory 23 years after primary plasma-derived hepatitis B vaccination: results of a randomized placebo-controlled trial cohort from China where endemicity is high.","volume":"29","author":"Wu","year":"2011","journal-title":"Vaccine"},{"key":"R18-20250615","doi-asserted-by":"crossref","first-page":"896","DOI":"10.4161\/hv.19989","article-title":"Persistence and immune memory to hepatitis B vaccine 20 years after primary vaccination of Thai infants, born to HBsAg and HBeAg positive mothers.","volume":"8","author":"Poovorawan","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"R19-20250615","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1471-2458-6-187","article-title":"Stages of development and injury patterns in the early years: a population-based analysis.","volume":"6","author":"Flavin","year":"2006","journal-title":"BMC Public Health"},{"key":"R20-20250615","first-page":"341","article-title":"Recovery and turnover rate of hepatitis B immunoglobulin in volunteers.","volume":"54","author":"Wahl","year":"1983","journal-title":"Dev Biol Stand"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003350","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:02:09Z","timestamp":1750003329000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,8]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003350","relation":{},"ISSN":["0891-3668"],"issn-type":[{"type":"print","value":"0891-3668"}],"subject":[],"published":{"date-parts":[[2021,12,8]]}}}